Vibegron
- Generic Name
- Vibegron
- Brand Names
- Gemtesa, Obgemsa
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28N4O3
- CAS Number
- 1190389-15-1
- Unique Ingredient Identifier
- M5TSE03W5U
- Background
Vibegron is a potent, selective beta-3 adrenergic receptor (Ξ²3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder, a condition associated with distressing symptoms of urge urinary incontinence, urgency, and urinary...
- Indication
Vibegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
- Associated Conditions
- Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 75
- Registration Number
- NCT06417177
- Locations
- πΊπΈ
University of Missouri-Columbia, Columbia, Missouri, United States
A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 85
- Registration Number
- NCT05491525
- Locations
- πΊπΈ
Albany Medical College, Albany, New York, United States
πΊπΈChildrens Hospital New Orleans, New Orleans, Louisiana, United States
πΊπΈWichita Urology Group, Wichita, Kansas, United States
Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB)
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 400
- Registration Number
- NCT05067478
- Locations
- πΊπΈ
Southern Urogynecology, West Columbia, South Carolina, United States
πΊπΈAssociated Urologists of North Carolina, Raleigh, North Carolina, United States
πΊπΈMedicus Alliance Clinical Research Organization Inc., Sugar Land, Texas, United States
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 276
- Registration Number
- NCT04103450
- Locations
- πΊπΈ
Clinical Research of Central Florida, Winter Haven, Florida, United States
πΊπΈAmerican Institute of Research, Los Angeles, California, United States
πΊπΈQuantum Clinical Trials, Miami, Florida, United States
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 1105
- Registration Number
- NCT03902080
- Locations
- πΊπΈ
Boston Clinical Trials Inc - Urology, Boston, Massachusetts, United States
πΊπΈAdvances In Health, Inc., Houston, Texas, United States
πΊπΈExcel Clinical Research - Internal Medicine, Las Vegas, Nevada, United States
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 222
- Registration Number
- NCT03806127
- Locations
- πΊπΈ
Mandeville Private Physician Group, LLC, Mandeville, Louisiana, United States
πΊπΈMedical Research Center of Connecticut LLC, Hamden, Connecticut, United States
πΊπΈSynexus Clinical Research US, Inc. - Desert Clinical Research, LLC, Mesa, Arizona, United States
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
- Conditions
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 506
- Registration Number
- NCT03583372
- Locations
- πΊπΈ
Coastal Clinical Research Inc., Mobile, Alabama, United States
πΊπΈDowntown L.A. Research Center Inc., Los Angeles, California, United States
πΊπΈWomen's Clinic of Lincoln PC, Lincoln, Nebraska, United States
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 1530
- Registration Number
- NCT03492281
- Locations
- πΊπΈ
Prime-Care Clinical Research, Laguna Hills, California, United States
πΊπΈKO Clinical Research, Fort Lauderdale, Florida, United States
πΊπΈVital Pharm Research Inc., Hialeah, Florida, United States
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01737684
A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4
- Registration Number
- NCT01500382
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.